Display options
Cite
Pillai G, Ceballos-Coronel ML. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med. 2013;1:2050312113513759doi: 10.1177/2050312113513759.
Pillai, G., & Ceballos-Coronel, M. L. (2013). Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE open medicine, 12050312113513759. https://doi.org/10.1177/2050312113513759
Pillai, Gopalakrishna, and Ceballos-Coronel, Maria L. "Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists." SAGE open medicine vol. 1 (2013): 2050312113513759. doi: https://doi.org/10.1177/2050312113513759
Pillai G, Ceballos-Coronel ML. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med. 2013 Nov 23;1:2050312113513759. doi: 10.1177/2050312113513759. eCollection 2013. PMID: 26770691; PMCID: PMC4687778.
Copy Download .nbib Format: NLM
Share it on

SAGE Open Med. 2013 Nov 23;1:2050312113513759. doi: 10.1177/2050312113513759. eCollection 2013.

Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.

SAGE open medicine

Gopalakrishna Pillai, Maria L Ceballos-Coronel

Affiliations

  1. Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA.

PMID: 26770691 PMCID: PMC4687778 DOI: 10.1177/2050312113513759

Abstract

Nanomedicine, the medical applications of devices based on nanotechnology, promises an endless range of applications from biomedical imaging to drug and gene delivery. The size range of the nanomaterials is strictly defined as 1-100 nm, although many marketed nanomedicines are in the submicron range of 100-1000 nm. The major advantages of using nanomaterials as a carrier for anticancer agents are the possibility of targeted delivery to the tumor; their physical properties such as optical and magnetic properties, which can be exploited for developing contrast agents for tumor imaging; their ability to hold thousands of molecules of a drug and deliver at the required site and also the ability to overcome solubility and stability issues. Currently, there are several nanotechnology-enabled diagnostic and therapeutic agents undergoing clinical trials and a few already approved by Food and Drug Administration. Targeted delivery of anticancer agents is achieved by exploiting a unique characteristic of the rapidly dividing tumor cells called "the enhanced permeability and retention effect." Nanoparticles with mean diameter between 100 and 200 nm or even above 200 nm have also been reported to be taken up by tumor cells via the enhanced permeability and retention effect. In addition to this passive targeting based on size, the nanoparticle surface may be modified with a variety of carefully chosen ligands that would interact with specific receptors on the surface of the tumor cells, thus imparting additional specificity for active targeting. Regional release of a drug contained in a nanoparticulate system by the application of external stimuli such as hyperthermia to a thermosensitive device is another innovative strategy for targeted delivery. Nanoparticles protect the enclosed drug from rapid elimination from the body, keep them in circulation for prolonged periods and often evade expulsion by the efflux pump mechanisms, which also leads to avoidance of development of resistance. This review focuses on the science and technology of Food and Drug Administration-approved cancer nanomedicines such as Abraxane, Doxil, DaunoXome and those drug-delivery systems that have reached an advanced stage of clinical development utilizing liposomes, albumin nanospheres, thermosensitive devices and gold nanoshells.

Keywords: Cancer nanomedicines; albumin-bound nanoparticles; approved products and in clinical development; gold nanoshells; liposomes; multidrug resistance; stimuli-sensitive release; targeted delivery

References

  1. J Liposome Res. 2002 Nov;12(4):301-9 - PubMed
  2. Sci Rep. 2013;3:1293 - PubMed
  3. J Urol. 2008 Feb;179(2):748-53 - PubMed
  4. Cancer Res. 1990 Feb 1;50(3):575-9 - PubMed
  5. Nanomedicine (Lond). 2010 Jun;5(4):597-615 - PubMed
  6. Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504 - PubMed
  7. Nature. 2003 Jun 5;423(6940):593-5 - PubMed
  8. Drug Discov Today. 2012 Feb;17(3-4):160-6 - PubMed
  9. J Clin Oncol. 2001 Jul 15;19(14):3312-22 - PubMed
  10. Ann Oncol. 2004 Mar;15(3):440-9 - PubMed
  11. J Clin Oncol. 1993 Nov;11(11):2186-93 - PubMed
  12. Nanomedicine (Lond). 2012 Aug;7(8):1133-48 - PubMed
  13. J Natl Cancer Inst. 1992 Dec 16;84(24):1909-15 - PubMed
  14. Int J Nanomedicine. 2006;1(4):375-83 - PubMed
  15. Invest New Drugs. 2012 Feb;30(1):282-9 - PubMed
  16. Int J Cancer. 2000 Apr 15;86(2):174-81 - PubMed
  17. Ann Oncol. 2002 Aug;13(8):1173-84 - PubMed
  18. Cancer. 1977 Nov;40(5):2046-52 - PubMed
  19. Biomed Res Int. 2013;2013:782041 - PubMed
  20. J Clin Oncol. 1995 Apr;13(4):996-1003 - PubMed
  21. Acad Radiol. 2005 Oct;12(10):1232-40 - PubMed
  22. Methods Mol Biol. 2010;624:101-17 - PubMed
  23. Cancer Res. 2009 Feb 15;69(4):1659-67 - PubMed
  24. Blood. 2010 Aug 12;116(6):915-25 - PubMed
  25. Int J Nanomedicine. 2007;2(4):567-83 - PubMed
  26. Curr Drug Metab. 2009 Oct;10(8):836-41 - PubMed
  27. Science. 2005 Jan 7;307(5706):58-62 - PubMed
  28. Clin Cancer Res. 2000 Jul;6(7):2903-12 - PubMed
  29. Cancer Lett. 2004 Jun 25;209(2):171-6 - PubMed
  30. Cancer Res. 2011 Sep 1;71(17):5678-87 - PubMed
  31. J Control Release. 2005 Dec 5;109(1-3):120-6 - PubMed
  32. Cancer Chemother Pharmacol. 1994;34(6):527-34 - PubMed
  33. Anticancer Drugs. 2003 Mar;14(3):239-46 - PubMed
  34. Int J Cancer. 2010 Mar 1;126(5):1235-45 - PubMed
  35. Nat Med. 2013 Feb;19(2):120 - PubMed
  36. Cancer Res. 2002 Sep 15;62(18):5381-5 - PubMed
  37. J Clin Oncol. 2005 Mar 20;23(9):1859-66 - PubMed
  38. Nanomedicine (Lond). 2007 Jun;2(3):351-74 - PubMed
  39. J Clin Oncol. 2000 Sep;18(17):3093-100 - PubMed
  40. Int J Nanomedicine. 2006;1(3):241-54 - PubMed
  41. Expert Opin Biol Ther. 2009 Jan;9(1):111-9 - PubMed
  42. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  43. Cancer. 2003 Jul 15;98(2):413-23 - PubMed
  44. Nat Nanotechnol. 2010 Dec;5(12):833-42 - PubMed
  45. J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 - PubMed
  46. J Control Release. 2000 Mar 1;65(1-2):271-84 - PubMed
  47. Nature. 1997 Nov 27;390(6658):404-7 - PubMed
  48. Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218 - PubMed
  49. Ann Oncol. 2005;16 Suppl 2:ii203-8 - PubMed
  50. J Biol Chem. 2001 Jun 1;276(22):19166-71 - PubMed
  51. Prog Lipid Res. 2002 Sep;41(5):392-406 - PubMed
  52. Hum Gene Ther. 2005 Sep;16(9):1097-109 - PubMed
  53. Pharm Res. 1994 Dec;11(12):1800-8 - PubMed
  54. Adv Enzyme Regul. 1990;30:357-73 - PubMed
  55. Eur J Cancer. 2002 Jul;38(10):1413-9 - PubMed
  56. J Transl Med. 2012 Oct 04;10:206 - PubMed
  57. Ann Surg Oncol. 2012 May;19(5):1595-601 - PubMed
  58. Cancer Chemother Pharmacol. 2004 Dec;54(6):514-24 - PubMed
  59. Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16 - PubMed
  60. Biochem Pharmacol. 1999 Apr 1;57(7):727-41 - PubMed
  61. Open Nanomed J. 2011 Jan 1;3:38-64 - PubMed
  62. Immunity. 2006 Feb;24(2):129-31 - PubMed
  63. Pharm Res. 2002 Jul;19(7):1061-7 - PubMed
  64. Clin Pharmacokinet. 2006;45(12):1153-76 - PubMed
  65. Cancer Res. 1992 Jun 15;52(12):3255-61 - PubMed
  66. Nat Rev Cancer. 2002 Jan;2(1):38-47 - PubMed
  67. Phys Chem Chem Phys. 2009 Nov 14;11(42):9772-8 - PubMed
  68. J Pharm Pharm Sci. 2003 May-Aug;6(2):292-301 - PubMed
  69. J Drug Deliv. 2013;2013:456409 - PubMed
  70. Pharmacol Rev. 1990 Sep;42(3):155-99 - PubMed
  71. Arch Neurol. 1995 Sep;52(9):912-7 - PubMed
  72. Radiology. 2007 Dec;245(3):824-30 - PubMed
  73. Nanomedicine (Lond). 2012 Oct;7(10):1577-90 - PubMed
  74. Cancer Metastasis Rev. 2001;20(1-2):87-93 - PubMed
  75. FEBS Lett. 1990 Jan 1;259(2):293-6 - PubMed
  76. Int J Nanomedicine. 2006;1(3):297-315 - PubMed
  77. Expert Rev Vaccines. 2008 Oct;7(8):1141-50 - PubMed
  78. J Control Release. 2005 May 5;104(1):103-11 - PubMed
  79. J Natl Cancer Inst. 1995 Apr 5;87(7):506-16 - PubMed
  80. J Drug Deliv. 2012;2012:581363 - PubMed
  81. Circ Res. 2003 Apr 18;92 (7):801-8 - PubMed
  82. Clin Pharmacokinet. 2001;40(7):539-51 - PubMed
  83. J Clin Oncol. 2011 Dec 1;29(34):4548-54 - PubMed
  84. Nano Lett. 2005 Sep;5(9):1797-808 - PubMed
  85. Expert Opin Pharmacother. 2012 Feb;13(3):395-406 - PubMed
  86. Cancer Res. 2006 Nov 1;66(21):10365-76 - PubMed
  87. Mol Pharm. 2005 Sep-Oct;2(5):373-83 - PubMed
  88. Lancet Oncol. 2002 Aug;3(8):487-97 - PubMed
  89. Oncogene. 1997 May 22;14(20):2475-83 - PubMed
  90. Biochim Biophys Acta. 2005 Oct 15;1716(2):77-96 - PubMed
  91. Expert Opin Pharmacother. 2006 Jun;7(8):1041-53 - PubMed
  92. Angiogenesis. 1999;3(4):291-3 - PubMed
  93. Adv Exp Med Biol. 2003;519:29-49 - PubMed
  94. Cancer Res. 2000 Aug 15;60(16):4440-5 - PubMed
  95. Expert Opin Pharmacother. 2008 Feb;9(2):301-9 - PubMed
  96. Pediatr Nurs. 1995 Sep-Oct;21(5):471-4, 490 - PubMed
  97. Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8 - PubMed
  98. Adv Drug Deliv Rev. 1995 Sep;16(2-3):215-233 - PubMed
  99. Pharm Res. 2004 Dec;21(12):2226-33 - PubMed
  100. Circ Res. 2000 Feb 4;86(2):E29-35 - PubMed
  101. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 - PubMed
  102. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 - PubMed
  103. Clin Cancer Res. 2006 Feb 15;12(4):1317-24 - PubMed
  104. Breast Cancer Res. 2002;4(3):95-9 - PubMed
  105. Br J Cancer. 2006 Sep 4;95(5):571-80 - PubMed
  106. Int J Hyperthermia. 2010;26(5):485-98 - PubMed
  107. Vasc Health Risk Manag. 2006;2(3):213-9 - PubMed
  108. Mol Pharm. 2007 Sep-Oct;4(5):730-8 - PubMed

Publication Types